NCT05003921WithdrawnPhase 1
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for ALS
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral Sclerosis
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This trial will study the safety and efficacy of intrathecal injection of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of amyotrophic lateral sclerosis
- Status (registry)
- Withdrawn
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 6 Aug 2021
- Start date
- Dec 2025
- Primary completion date
- Sept 2028
- Lead sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT05003921
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous organ transplant
- Continued drug abuse
Other illness
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
- Hypersensitivity to sulfur
Lab values
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
Other
- Pregnancy
- Anticoagulation medicine use
- Pre-menopausal women not using contraception
Who the study is looking for
- Diagnosis of Amyotrophic Lateral Sclerosis.
- Understanding and willingness to sign a written informed consent document
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.